Quince Therapeutics, Inc. QNCX 深 沪
等待开盘 06-24 09:30:00 美东时间
0.9682
+0.041
+4.38%
华盛通- 最 高1.00
- 今 开0.92
- 成交量 40.81万股
- 最 低 0.90
- 昨 收 0.9276
- 总市值 1893.73万
- 52周最高 45.499
- 市盈率 静 --
- 换手率 2.09%
- 52周最低 0.79
- 委 比 -89.37%
- 总股本 1955.93万
- 历史最高 1219.80
- 量 比 1.32
- 振 幅 10.78%
- 历史最低 0.80
- 每 手 1
- 风险率 11.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
今天 14:08
Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Overweight rating and announces Price Target of $4.
今天 00:10
Quince Therapeutics Stockholders Approve Reverse Split Authorization
Quince Therapeutics ( ($QNCX) ) has provided an update. On June 11, 2026, Quinc...
06-12 06:42
Quince Therapeutics Announces Acquisition Of Orphai Therapeutics In Stock-For-Stock Deal; Quince Enters Concurrent Private Placement Agreement To Raise Up To $187M
The acquisition is structured as a stock-for-stock merger, pursuant to which all outstanding equity interests of Orphai will be exchanged based on a fixed exchange ratio for a combination of 3,258,517 shares common
05-18 21:33
Quince Therapeutics Reports Phase 2a Data For LAM-001 In Pulmonary Hypertension-Associated ILD, Demonstrated Clinically Meaningful Improvement In Multiple Assessments Of Lung Function, Including Improvement In 6MWD Of 67.4 Meters And PVR Reduction Of 33.9% At 24 Weeks; Phase 2b Trial In PH-ILD To Initiate In Mid-2026, With Topline Data Anticipated In Q1 2028
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD
05-18 21:31
Quince Therapeutics Appoints June Bray to Board
Quince Therapeutics ( ($QNCX) ) has shared an update. On April 22, 2026, Quince...
04-23 05:33
Why Levi Strauss Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Levi Strauss (LEVI) reported strong Q1 2026 results, raising revenue & earnings guidance. Other pre-market gainers include QNCX, VSME, UCAR, IPW, JEM, AZI, GPUS, AXTI, IPX.
04-08 17:33
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Lunai Bioworks (NASDAQ:LNAI) stock moved upwards by 47.2% to $0.41 dur...
04-08 01:05
Quince Therapeutics Eliminates EIB Debt, Boosts Flexibility
Quince Therapeutics ( ($QNCX) ) has provided an update. On March 27, 2026, Quin...
03-30 22:23
BRIEF-Quince Therapeutics Settles Approximately $16.4 Million Of Debt
BRIEF-Quince Therapeutics Settles Approximately $16.4 Million Of Debt March 30 (Reuters) - Quince Therapeutics Inc QNCX.O : QUINCE THERAPEUTICS SETTLES APPROXIMATELY $16.4 MILLION OF DEBT Source text: ID:nBw9dLCyra Further company coverage: QNCX.O (( Reuters.Briefs@thomsonreuters.com ;))
03-30 22:09
